BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 1,130 filers reported holding BAXTER INTL INC in Q1 2022. The put-call ratio across all filers is 1.41 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $222,229 | -3.0% | 4,360 | +2.3% | 0.09% | -8.4% |
| Q3 2022 | $229,000 | -17.3% | 4,260 | -1.2% | 0.10% | -12.8% |
| Q2 2022 | $277,000 | -21.8% | 4,310 | -5.5% | 0.11% | -0.9% |
| Q1 2022 | $354,000 | -7.6% | 4,560 | +2.2% | 0.11% | -2.7% |
| Q4 2021 | $383,000 | +6.7% | 4,460 | 0.0% | 0.11% | +2.7% |
| Q3 2021 | $359,000 | +4.1% | 4,460 | 0.0% | 0.11% | +6.8% |
| Q2 2021 | $345,000 | -5.0% | 4,460 | +3.7% | 0.10% | -10.4% |
| Q1 2021 | $363,000 | +9.7% | 4,300 | +4.4% | 0.12% | -1.7% |
| Q4 2020 | $331,000 | -6.5% | 4,120 | -6.4% | 0.12% | -18.8% |
| Q3 2020 | $354,000 | -6.6% | 4,400 | 0.0% | 0.14% | -10.6% |
| Q2 2020 | $379,000 | +6.2% | 4,400 | 0.0% | 0.16% | -11.0% |
| Q1 2020 | $357,000 | -3.0% | 4,400 | 0.0% | 0.18% | +25.7% |
| Q4 2019 | $368,000 | -10.5% | 4,400 | -6.4% | 0.14% | -6.5% |
| Q3 2019 | $411,000 | +6.8% | 4,700 | 0.0% | 0.15% | +6.9% |
| Q2 2019 | $385,000 | -9.0% | 4,700 | -9.6% | 0.14% | -7.7% |
| Q1 2019 | $423,000 | +23.7% | 5,200 | 0.0% | 0.16% | +10.6% |
| Q4 2018 | $342,000 | -14.7% | 5,200 | 0.0% | 0.14% | -0.7% |
| Q3 2018 | $401,000 | +4.4% | 5,200 | 0.0% | 0.14% | +3.6% |
| Q2 2018 | $384,000 | +13.6% | 5,200 | 0.0% | 0.14% | +10.5% |
| Q1 2018 | $338,000 | +0.6% | 5,200 | 0.0% | 0.12% | +0.8% |
| Q4 2017 | $336,000 | +0.9% | 5,200 | -1.9% | 0.12% | +12200.0% |
| Q3 2017 | $333,000 | +1.8% | 5,300 | -1.9% | 0.00% | -99.2% |
| Q2 2017 | $327,000 | +16.8% | 5,400 | 0.0% | 0.13% | +13.2% |
| Q1 2017 | $280,000 | +1.1% | 5,400 | -13.6% | 0.11% | -2.6% |
| Q4 2016 | $277,000 | -9.8% | 6,250 | -3.1% | 0.12% | -10.7% |
| Q3 2016 | $307,000 | +5.1% | 6,450 | 0.0% | 0.13% | +6.5% |
| Q2 2016 | $292,000 | +10.2% | 6,450 | 0.0% | 0.12% | +8.8% |
| Q1 2016 | $265,000 | +7.7% | 6,450 | 0.0% | 0.11% | +3.7% |
| Q4 2015 | $246,000 | +14.4% | 6,450 | -1.5% | 0.11% | +9.0% |
| Q3 2015 | $215,000 | -53.1% | 6,550 | 0.0% | 0.10% | -49.0% |
| Q2 2015 | $458,000 | +2.0% | 6,550 | 0.0% | 0.20% | +7.7% |
| Q1 2015 | $449,000 | -6.5% | 6,550 | 0.0% | 0.18% | +12.3% |
| Q4 2014 | $480,000 | -3.0% | 6,550 | -5.1% | 0.16% | -4.1% |
| Q3 2014 | $495,000 | -51.8% | 6,900 | -51.3% | 0.17% | -9.6% |
| Q2 2014 | $1,026,000 | -1.7% | 14,178 | 0.0% | 0.19% | -0.5% |
| Q1 2014 | $1,044,000 | +5.9% | 14,178 | 0.0% | 0.19% | +3.3% |
| Q4 2013 | $986,000 | +5.8% | 14,178 | 0.0% | 0.18% | +7.7% |
| Q3 2013 | $932,000 | -36.3% | 14,178 | -33.0% | 0.17% | -6.1% |
| Q2 2013 | $1,464,000 | – | 21,150 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |